![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pharma Blog Watch
Pharma Blog Watch
September 19, 2006
Drug Delivery Patent
Claims (Patent Baristas)
In his entry, blogger Stephen Albainy-Jenei discusses AstraZeneca's request
to the FDA for a decision on "whether patents directed to drug delivery
systems, such as inhalation devices, that do not recite the approved active
ingredient or formulation," should be included in the Orange Book.
FDA regulations stipulate that "patents that claim the 'drug product' that is the subject of the [new drug application] must be listed, but also states that patents claiming 'packaging' must not be listed," he notes.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct